William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area
- blonca9
- Nov 30, 2023
- 1 min read
Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into the radiopharmaceutical space, and discusses AASLD data, the Seagen FTC review, and upcoming RSV data from Icosavax.